Guiding Evidence Based Therapy Using Biomarker Intensified Treatment

A trial with no phase registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 894 participants.

Also called NCT01685840

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 894 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01685840
Other papers using this trial's data
  • Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial: A Secondary Analysis of a Randomized Clinical Trial JAMA cardiology, 2020-07-01 DOI, PubMed 32319999, PMC7177636 Not in the PMC Open Access subset.
  • Clinical factors related to morbidity and mortality in high-risk heart failure patients: the GUIDE-IT predictive model and risk score European journal of heart failure, 2019-06 DOI, PubMed 30919549, PMC6830509 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Differences in NT-proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction Journal of the American Heart Association, 2021-05-18 DOI, PubMed 33955231, PMC8200692 In the PMC Open Access subset under CC BY-NC.
  • Economic and Quality-of-Life Outcomes of Natriuretic Peptide-Guided Therapy for Heart Failure Journal of the American College of Cardiology, 2018-11-27 DOI, PubMed 30466512, PMC6261478 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial JAMA, 2017-08-22 DOI, PubMed 28829876, PMC5605776 In the PMC Open Access subset under a licence that is not Creative Commons.
  • NT-proBNP Goal Achievement Is Associated With Significant Reverse Remodeling and Improved Clinical Outcomes in HFrEF JACC. Heart failure, 2019-02 DOI, PubMed 30611722
  • Natriuretic Peptide Response and Outcomes in Chronic Heart Failure With Reduced Ejection Fraction Journal of the American College of Cardiology, 2019-09-03 DOI, PubMed 31466618, PMC6719723 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Obesity and Serial NT-proBNP Levels in Guided Medical Therapy for Heart Failure With Reduced Ejection Fraction: Insights From the GUIDE-IT Trial Journal of the American Heart Association, 2021-04-06 DOI, PubMed 33754794, PMC8174357 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01685840. Randomized; no masking; primary purpose treatment. Start 2012-12 (registry gives no type); primary completion 2016-09-20 (actual). Results posted on 2017-12-12.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Guiding Evidence Based Therapy Using Biomarker Intensified Treatment
Acronym
GUIDE-IT
Condition
Heart Failure
Intervention (Other)
Usual Care
Intervention (Device)
Biomarker-guided care NT-proBNP (natriuretic peptide)
Lead sponsor
Duke University (class: other)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct01685840
Content hash
f6f399c09cb1a62d09793680084cf2026de8d20ecf6a4c0b494e1e409e1083c4